Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332956 · ClinicalTrials.gov registry record · Phase 2
Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
A Phase 2 study, sponsored by DynPort Vaccine Company LLC, A GDIT Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00332956: Completed Phase 2 study, sponsored by DynPort Vaccine Company LLC, A GDIT Company.
NCT00332956 is a Phase 2 study that has completed, run by DynPort Vaccine Company LLC, A GDIT Company. The registered enrollment target is 400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00332956, a Phase 2 study, has completed, sponsored by DynPort Vaccine Company LLC, A GDIT Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
This Phase 2(a) clinical trial is designed as a dose-blinded, block-randomized, multi-center study to select a dosage and schedule of rF1V vaccine for further studies based on the immune response up to Day 210. Additional immunogenicity and safety/reactogenicity data will be collected through Day 540. Selection of dosage and schedule will be based on GMCs and seroconversion rates for anti-F1, anti-V and anti-rF1V antibody titers. Approximately 400 healthy adult volunteers will be enrolled (100 per group) in this study.
Interventions
- BIOLOGICAL rF1V vaccine
- BIOLOGICAL rFIV vaccine
- BIOLOGICAL rF1V vaccine 160 mcg given on Study Days 0, 56, 182
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00332956 record still lists
NCT00332956 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher).
The record links to 0 conditions, and to 3 interventions - of which rF1V vaccine is the first listed.
NCT00332956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00332956 about?
NCT00332956 is a clinical study titled "Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers". This Phase 2(a) clinical trial is designed as a dose-blinded, block-randomized, multi-center study to select a dosage and schedule of rF1V vaccine for further studies based on the immune response up to Day 210. Additional immunogenicity and safety/reactogenicity data will be collected through Day 54...
What is the current status of trial NCT00332956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2006-05. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00332956?
The interventions under investigation include: rF1V vaccine (BIOLOGICAL), rFIV vaccine (BIOLOGICAL), rF1V vaccine 160 mcg given on Study Days 0, 56, 182 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00332956?
This trial is sponsored by DynPort Vaccine Company LLC, A GDIT Company, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00332956's enrollment target sits among peer trials
400 96th of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia